Acer Therapeutics Inc.
222 Third Street
Suite 2240
Cambridge
Massachusetts
02142
United States
Website: http://www.acertx.com/
Email: jdavis@acertx.com
21 articles with Acer Therapeutics Inc.
-
Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/13/2019
NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2019 and provided an update on the Company’s recent corporate developments. “We have been very active as we continue to progress the development of
-
Clinical Catch-Up: October 28-Nov 1
11/4/2019
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. -
Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle DisordersResults Expected in Q1 2020 with a Planned NDA Submission in Q1 2021
10/28/2019
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of Part A in a pivotal trial evaluating bioavailability and bioequivalence of ACER-001 for the treatment of Urea Cycle Disorders (UCDs).
-
FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019
8/27/2019
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Acer Therapeutics Inc. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Acer securities purchased between September 25, 2017 and June 24, 2019, inclusive.
-
The Complete Response Letter indicated the company will need to run an “adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS.”
-
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
-
Acer Therapeutics Announces In-license of Osanetant from Sanofi
1/2/2019
Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist
-
Acer Therapeutics, headquartered in Newton, Mass., in-licensed osanetant, a clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist from Paris-based Sanofi.
-
Acer Therapeutics Expands Management Team with the Appointment of Three Executives and One New Key Hire
2/5/2018
The new hires support Acer’s progression from development to potential commercialization of EDSIVO.
-
Acer Therapeutics Announces Partial Exercise of Over-Allotment Option in Public Offering
12/28/2017
Acer intends to use the net proceeds from this offering to fund its research and development efforts, to seek regulatory approval for EDSIVO.
-
Acer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
12/15/2017
Acer intends to use the net proceeds from this offering to fund its research and development efforts, to seek regulatory approval for EDSIVO and more.
-
Acer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
12/12/2017
Acer intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering.
-
Acer Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
12/12/2017
The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Acer, are expected to be approximately $11.0 million
-
Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/14/2017
Cash and cash equivalents were $8.4 million as of September 30, 2017, compared to $1.8 million as of December 31, 2016.
-
Acer Therapeutics Welcomes Two New Members To Its Board Of Directors
10/12/2017
-
Acer Therapeutics Appoints Dr. William T. Andrews As Chief Medical Officer
10/5/2017
-
Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial Of EDSIVO (Celiprolol) For Treatment Of Vascular Ehlers-Danlos Syndrome
9/25/2017
-
Acer Therapeutics And Opexa Therapeutics Close Merger And Financing
9/20/2017
-
Acer Therapeutics Forms Scientific Advisory Board
12/20/2016
-
Acer Therapeutics Obtains Exclusive License To Celiprolol Pivotal Clinical Data From AP-HP
12/13/2016